bioPics.png

Paul Weber, President and Chief Business Officer, Founder
Mr. Weber brings extensive marketing, commercialization and international business development experience with both large multinational and growth stage medical and technology companies. Prior to joining Perimeter Medical, he led Business Development and Marketing for Covalon Technologies. In this capacity he helped to transition the company from a technology focus to a commercially focused organization, building out OEM, domestic and international distribution channels. At Sentinelle he led Business Development and Marketing, growing the company from start-up revenues to greater than $18 million in sales in 2 ½ years. After being acquired by Hologic Inc. for $105 million, Mr. Weber led Marketing, integration, and OEM and International Distribution relationships. Mr. Weber has also had leadership roles in business development and product management capacities with Johnson and Johnson, Christie Digital and has consulted for numerous technology start-ups on growth strategies. He has developed and taught MBA courses in Marketing and Commercialization of Technology and holds a BA in Psychology and an MBA from Wilfrid Laurier University.


bioPics.png

Suzanne Foster
 Mrs. Foster is a proven business leader, a breast cancer survivor, and a passionate patient advocate. As general manager of Medtronic Transformative Solutions, Mrs. Foster led the development and acquisition of several technologies that are improving the way critical procedures are performed and thereby advancing patient care. During her tenure at Medtronic, the business achieved double-digit revenue growth for the past seven years and experienced significant global market adoption.

Mrs. Foster is a frequent speaker on topics related to finding ways to advance technology and procedural innovation in breast cancer care. In March 2018, The National Consortium of Breast Centers (NCBC) awarded her with their Inspiration Award, which recognizes someone who has gone above and beyond towards improving breast cancer care.  Mrs. Foster has also been recognized for her work in employee engagement and diversity. Notable achievements include:

— #1 Best Place to Work in New Hampshire, Business NH Magazine, 2014-2017
— Business Excellence Award in Manufacturing, New Hampshire Business Review, 2017

Mrs. Foster has a BA in Communication from University of New Hampshire, M.Ed in Psychology from Notre Dame College, JD Law from Suffolk Law School and a Masters in Public Health (Law and Health Policy) from Harvard School of Public Health.


Paul Magnin, PHD  
Dr. Magnin spent 17 years as a key contributor to Hewlet-Packard's Ultrasound Imaging business. He was the General Manager of Hewlett-Packard's Imaging Systems business from January 1996 through 1998. From 1998 through 2003, Dr. Magnin was the President and CEO of LightLab Imaging, a medical device start-up company. LightLab developed a proprietary Optical Coherence Tomography technology that employs infrared light to make images with resolution on the micron scale for Cardiology, Endoscopy, Neurology, and Surgical Microscopy. Subsequently he was the Founder and President of Novelis, Inc. a privately funded start-up focused on guiding therapy for Interventional Cardiology applications. Novelis was sold to Volcano Corporation in 2008. Dr. Magnin is an advisor and board member of a number of medical device start-up companies. He holds over 16 patents and has authored over 20 scientific journal articles. He has been studying and working in medical imaging since 1977 while an undergraduate at Princeton University. In 1981 he completed his doctorate in Biomedical Engineering at Duke University where he was part of the Ultrasonic Imaging research team.


Franklyn Prendergast, MD
Dr. Prendergast has held senior positions within Mayo Clinic: Chair, Department of Biochemistry & Molecular Biology; Director for Research, Mayo Clinic Rochester,‘89-‘92. Member of the Board of Governors for Mayo Clinic in Rochester; Mayo Clinic Board of Trustees,‘92-‘09; Mayo Clinic’s Board of Governors, ‘99-‘06. Mayo Distinguished Investigator, Emeritus Director of the Mayo Clinic Comprehensive Cancer Center and Emeritus Director of Mayo Center for Individualized Medicine.
 
Frank also served extensively for the National Institutes of Health, Board of Advisors for Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of National Cancer Institute; National Cancer Advisory Board.
 
He has received the following honors and awards: Rhodes Scholarship; DSc Purdue University and University West Indies, Outstanding Graduate from University West Indies; Outstanding Graduate College of Biological Sciences from University of Minnesota; Musgrave Gold Medal Institute of Jamaica.
 
Frank holds a medical degree with honors from University of West Indies; Oxford University Rhodes Scholar M.A. degree in physiology. After internal medicine residency at Mayo Clinic, he obtained the Ph.D. degree in biochemistry at University of Minnesota/Mayo Graduate School.

bioPics.png

Stephen Ireland
Mr. Ireland is the Healthcare Principal at Roadmap Capital and brings more than 25 years of experience in healthcare. As the former Senior Vice-President, Business Development at TransTech Pharma, Mr. Ireland managed transactions in 2006 and 2010 with Pfizer and Forest Laboratories, respectively, valued in excess of $2 billion in potential upfront fees and milestones, each with recurring double-digit royalties. Mr. Ireland brings international experience in business development, clinical development, research, sales, marketing and executive management to Perimeter's board.

bioPics.png

Hugh Cleland
Mr. Cleland is co-founder and principal at Roadmap Capital, and Portfolio Manager of the Roadmap Innovation Funds. Mr. Cleland has a Bachelor of Arts (Honours, 1992/97) from Harvard University and earned his CFA designation in 2001. He was founding portfolio manager at Northern Rivers Capital Management (“Northern Rivers”), where he managed the Northern Rivers Innovation Fund from May of 2001 until Northern Rivers was acquired by BluMont Capital in February of 2010. He co-founded Roadmap Capital Inc. in the summer of 2013. Roadmap and its investors have now invested more than $120M in VC-stage tech companies. Sectors include semiconductors, material sciences, and medical devices. Mr. Cleland is now a member of the Board of Directors of Ubilite Inc and Perimeter Medical Imaging, and is an observer on the Board of Peraso Technologies and MMB Networks.  Prior to Northern Rivers, Mr. Cleland also held various roles at Midland Walwyn Capital and Interward Capital Corporation.

Dave Lacey
Mr. Lacey is the President and Chief Executive Officer of Brookfield RPS and responsible for developing and leading the company’s business strategy. He also directly spearheads both domestic and international corporate development activities, supports business development efforts and leads the executive team.  Prior to joining Brookfield seven years ago, Dave helped found three companies and co-managed a venture capital fund at OMERS/Borealis. Mr. Lacey has served on various public and not-for-profit boards and is currently the Brookfield appointee in its joint-venture with Berkshire Hathaway HomeServices. He also serves on the Enactus and Children’s Wish Ontario boards. Dave holds a B.A. from the University of Western Ontario and is an MBA graduate from Wilfrid Laurier University.


bioPics.png

Ted James, MD
A member of the BIDMC/Harvard health system, Dr. Ted James manages the surgical care of breast cancer patients. He performs advanced breast surgical oncology procedures including oncoplastic and minimally invasive breast surgery. Dr. James also takes an active role promoting quality initiatives in cancer care delivery. He is active in research on improving outcomes in breast cancer surgery, including margin control during breast conserving surgery.

Dr. James employs a multidisciplinary, team-based approach to cancer care and believes that patients should be key members of the treatment decision-making process. He educates patients about their diagnosis and addresses their treatment priorities. He believes that care must also be compassionate and focus on the entire person including their physical, emotional and spiritual well-being.

In addition to his medical and surgical training, Dr. James obtained a Health Care Management degree from Harvard. Dr. James is also faculty at Harvard Medical School and serves in leadership roles with the Commission on Cancer and American Cancer Society. He is a fellow of the American College of Surgeons and member of the Society of Surgical Oncology and American Society of Breast Surgeons.


bioPics.png

 
 

Hank Schmidt, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec scelerisque quam et ligula ultricies, a rhoncus quam pellentesque. Aliquam dapibus, magna ut venenatis fermentum, odio magna vehicula nunc, a dictum lorem odio vel mauris. Nam rhoncus, nulla at dapibus ultricies, nulla felis suscipit tellus, at convallis libero nisl in odio. Suspendisse condimentum quam sit amet elit efficitur, ac pretium lectus interdum. Suspendisse potenti. Integer elementum neque ex, vitae rhoncus ligula aliquam porttitor. Maecenas in elementum purus. Nulla mattis, felis a euismod tincidunt, arcu tortor malesuada quam, at porttitor felis orci at eros. Aenean ut venenatis orci. Curabitur vitae dui nec enim tristique imperdiet ac nec arcu. Donec vitae tempus augue. Donec id erat at justo malesuada ultricies nec sit amet leo. Maecenas porta suscipit viverra. Curabitur a elit quis diam luctus feugiat. Mauris vitae nunc sed ante venenatis pharetra.

Proin ipsum nunc, varius sit amet massa id, commodo accumsan est. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Vestibulum vestibulum nisl nec vehicula ultrices. In a turpis non eros dapibus auctor. Cras congue odio sed sapien varius vehicula. Etiam aliquam justo turpis, molestie consequat erat mollis ut. Vivamus nec rhoncus erat.

 

 

 
 

Frank Prendergast, MD
Dr. Prendergast has held senior positions within Mayo Clinic: Chair, Department of Biochemistry & Molecular Biology; Director for Research, Mayo Clinic Rochester,‘89-‘92. Member of the Board of Governors for Mayo Clinic in Rochester; Mayo Clinic Board of Trustees,‘92-‘09; Mayo Clinic’s Board of Governors, ‘99-‘06. Mayo Distinguished Investigator, Emeritus Director of the Mayo Clinic Comprehensive Cancer Center and Emeritus Director of Mayo Center for Individualized Medicine.
 
Dr. Prendergast also served extensively for the National Institutes of Health, Board of Advisors for Division of Research Grants; National Advisory General Medical Sciences Council; Board of Scientific Advisors of National Cancer Institute; National Cancer Advisory Board.
 
He has received the following honors and awards: Rhodes Scholarship; DSc Purdue University and University West Indies, Outstanding Graduate from University West Indies; Outstanding Graduate College of Biological Sciences from University of Minnesota; Musgrave Gold Medal Institute of Jamaica.
 
Dr. Prendergast holds a medical degree with honors from University of West Indies; Oxford University Rhodes Scholar M.A. degree in physiology. After internal medicine residency at Mayo Clinic, he obtained the Ph.D. degree in biochemistry at University of Minnesota/Mayo Graduate School.


bioPics.png

Doug Janzen
Mr. Janzen has been involved in the Life Sciences industry for the past 19 years. He currently is the Founder and President of NorthView Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Prior to that, he was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300M from investors and completed over $1Billion in licensing deals during his tenure. In 2010 Cardiome’s lead product Brinavess was approved and launched in Europe by Merck. Prior to that, Mr. Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr. Janzen is a past winner of Vancouver’s Top 40 under 40 award, is the past Chairman of Life Sciences British Columbia, has served as a Director of Biotech Canada and sits as a Director on a number of public and private boards.


bioPics.png

Brian Wilson, PHD
Dr. Wilson leads an internationally recognized R&D program in optics-based biomedical applications, with a primary translational / clinical focus. Dr. Wilson has published over 300 peer-reviewed papers in basic, translational and clinical research, and has trained more than 60 graduate students and postdoctoral and clinical fellows. He holds or has held several international Visiting Appointments (Harvard, USA; Saõ Paulo, Brazil; Fujian, China; Western Australia) and is involved in many national and international collaborations.

 

bioPics.png

Gordon Cheung, MD
Dr. Cheung is Medical Director of MRI/CT at CML HealthCare, one of the largest medical imaging practices in Canada. He is Consultant in Medical Imaging, Division of Neuroradiology and Interventional Neuroradiology at Sunnybrook Health Sciences Centre; and Assistant Professor at the University of Toronto. From 1990 to 2003, Dr. Cheung was the Clinical Director of MRI at Sunnybrook Health Sciences Centre. Dr. Cheung is also an entrepreneur, a founding partner of TUC Managed IT Solutions, and a founder of Excelion Technology.